Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37 results about "Protein link" patented technology

In nervous system: Neurotransmitters and neuromodulators …activation by receptor proteins of linking proteins, which move across the membrane, bind to channel proteins, and open the channels. Another system is the cyclic adenosine monophosphate (cAMP) system.

Fusion protein binding specifically to constant region of antibody, method of preparing the fusion protein, and method of isolating antibody using the fusion protein

A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.
Owner:SAMSUNG ELECTRONICS CO LTD

Therapeutic compounds structurally-linked to bacterial polypeptides

InactiveUS6913750B2Stabilizing the pilus-protein portionBiocideAntibody mimetics/scaffoldsMicroorganismProtein subunit
A protein construct comprising a pilus protein portion, preferably a structurally stabilized pilus-protein, and an additional, or effector, portion other than a pilus protein or chaperone and wherein said effector portion serves to stabilize the pilus protein portion and to confer a therapeutic activity, such as vaccine activity or anti-microbial or anticancer activity, on the protein construct is disclosed. Such effector portion commonly comprises a donor strand complementary segment capable of structurally stabilizing a pilus protein subunit and attaching the auxiliary portion to said subunit to form the pilus protein analog of the invention. Methods of using said protein constructs are also disclosed as well as the formation and use of analogs comprising fragments of a pilus protein linked to effector components to produce immunogenic and / or therapeutic activity.
Owner:MEDIMMUNE LLC +1

Method for Making Targeted Therapeutic Agents

InactiveUS20080199499A1Rapid and efficient identification and isolation and productionEffective and low methodAntibody mimetics/scaffoldsLibrary screeningDisease markersCross linker
Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair.
Owner:PROTEONOVA

Assay for inhibitors of CIP/KIP protein degradation

An assay and system compatible with high throughput screening (HTS) that is capable of identifying inhibitors, such as small-molecule inhibitors, of the degradation of the Cdk inhibitor p21, are described. The assay is based on the use of fusion protein comprising (i) a p2 polypeptide; and (i) a reporter protein linked to the C-terminal of said p21 polypeptide, wherein the fusion protein has a half-life that is similar to that of the p21 polypeptide. Inhibitors identified by this assay may be useful to inhibit the proliferation of tumor cells, and thus for the treatment of cancers.
Owner:UNIV DE MONTREAL

Functional screening

Screening methods for identifying molecules that interact with and / or regulate accumulation and stabilization of unstable proteins are provided. The screening methods involve generation of chimeric proteins comprising a region of an unstable protein linked to a region of a marker gene product. Changes in the levels of the unstable protein, due to accumulation, and / or stabilization and / or hyperaccumulation are then determined by analyzing the change in the marker gene product level. The marker gene product can be an antibiotic resistance gene that confers antibiotic resistance by stoichiometrically binding to the antibiotic or it can be a fluorescent protein region. Thus, antibiotic resistance screening or fluorescence imaging or cell sorting methods can be used to detect changes in the levels of the unstable chimeric proteins. Unstable proteins suitable for this screening method include, but are not limited to, membrane proteins such as ion channels, receptors, or presenilins.
Owner:CHICAGO UNIV OF THE

Process for production of a recombinant protein and a fusion protein

This invention provides a recombinant protein expression system using a host and cell-free translation system, and is capable of universally expressing a large amount of any protein as soluble protein, while preventing toxicity in hosts, formation of inclusion bodies, and decomposition with proteases. Such may be achieved by expressing the desired protein as a fusion protein with chaperonins, such as about 60 kDa molecular chaperones, 60 kDa heat shock proteins, or thermosomes, and accommodating the desired protein inside of a stereostructure of a chaperonin. The present invention provides a process for producing a protein, which comprises transcribing and translating a gene containing a gene encoding the linked chaperonin subunits and a gene encoding a desired protein thereby synthesizing a fusion protein having the desired protein linked via a peptide linkage to the linked chaperonin subunits.
Owner:SEKISUI CHEM CO LTD

Method for making targeted therapeutic agents

ActiveUS20110212114A1Rapid and efficient identification and isolation and productionEffective and low methodAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsDisease markersCross linker
Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair.
Owner:PROTEONOVA

Vacuole targeting peptide and nucleic acid

The present invention relates to a plant vacuole targeting sequence X1X2X3PX4 wherein X1 is a hydrophobic amino acid, X2 is a basic amino acid, X3 is a hydrophobic amino acid, P is proline; and X4 is a hydrophilic amino acid, such as the sequences IRLPS, IKLPS, LRLPS and LKLPS. The vacuole targeting sequence may be present in a chimeric protein linked to an amino acid sequence of a heterologous protein to facilitate vacuole vacuole targeting of the expressed chimeric protein in a plant cell. The invention is applicable to production of expressed, chimeric proteins in monocots and dicots, and in particular monocots such as cereals and sugarcane.
Owner:SUGAR IND INNOVATION

Blocking method for activated quantum dots

The invention provides a blocking method for activated quantum dots. The activated quantum dots are blocked by adopting polymer inert protein formed by cross-linking reaction of 1-ethyl-3-3-(3-dimethyl aminopropyl)-carbodiimide (EDC) and inert protein. The method disclosed by the invention has the advantages that effective blocking of the surfaces of the activated quantum dots can be ensured and protein linking in the blocking process is firmer, and thereby the sensitivity and the stability of a reagent are improved and basic performance of the quantum dot immunochromatography reagent is improved. The invention also aims at providing application of the method in an immunofluorescence assay kit for the quantum dots.
Owner:NANJING VAZYME MEDICAL TECH CO LTD +1

Modified PE40 toxin fusion proteins

We have modified PE40 toxin by removing at least two of its four cysteine amino acid residues and have formed hybrid molecules containing modified PE40 linked to a cell recognition protein that can be an antibody, a growth factor, a hormone, a lymphokine, or another polypeptide cell recognition protein for which a specific cellular receptor exists whereby the modified PE40 toxin is directed to cell types having receptors for the cell recognition protein linked to the modified PE40.
Owner:MERCK & CO INC

Protein link prediction algorithm fusing community structure and node degree local path similarity

The invention discloses a protein link prediction algorithm fusing community structure and node degree local path similarity. The purpose of the algorithm is to predict potential links in a protein interaction network. The method mainly comprises the following steps: constructing an adjacent matrix; detecting a community structure; constructing a training set and a test set; calculating communitycompactness indexes; calculating local path similarity based on the node degree; and calculating similarity values among all the nodes which are not linked. Existing link prediction methods mostly utilize common neighbor information of nodes, and do not consider contribution of protein community structure information to link prediction. Therefore, the defects of a method based on local informationsimilarity and a protein interaction prediction method based on a community structure are considered; the invention provides a protein link prediction method fusing community structure and node degree local path similarity, and link prediction is carried out in combination with a topological structure between proteins while community information in a protein interaction network is considered.
Owner:CHANGCHUN UNIV OF TECH

Method for the secretory production of heterologous protein in escherichia coli

The present invention relates to a signal sequence peptide for the improvement of extracellular secretion efficiency of a heterologous protein in E. coli. More particularly, the present invention relates to a gene construct for the improvement of extracellular secretion efficiency of the said heterologous protein in E. coli, which comprises a polynucleotide encoding a recombinant protein composed of the heterologous protein linked to C-terminal of the signal sequence peptide represented by SEQ. ID. NO. 3. The present invention contributes to the improvement of extracellular secretion efficiency of a recombinant protein, so that it can be effectively applied to the production of a recombinant protein.
Owner:KOREA INST OF SCI & TECH

Factor viii complex with xten and von willebrand factor protein, and uses thereof

The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
Owner:BIOVERATIV THERAPEUTICS INC

Cell penetrating protein-antibody conjugates and methods of use thereof

The present aspect provides cell penetrating conjugates. The conjugate includes the non-cell-penetrating protein linked by a phosphorothioate nucleic acid, wherein the phosphorothioate nucleic acid enhances intracellular delivery of the non-cell-penetrating protein. The invention also provides methods and kits comprising the conjugates provided herein.
Owner:CITY OF HOPE

Protein identification method and system

InactiveUS20150039240A1Information be useTime wastingProteomicsGenomicsBioinformaticsProtein
When a terminal sequence to be investigated is specified (S1), a corresponding protein is extracted from a database containing known proteins linked with terminal sequences (S2). If one protein cannot be uniquely identified (“No” in S5), amino-acid residues to be bonded to the target terminal sequences are selected, and new terminal sequences with the selected amino-acid residues respectively added are created for further investigation (S7). Each new terminal sequence is examined as to whether or not one protein can be uniquely identified from it, and if not so, another amino-acid residue is added. While such processes are repeated, if it has been found that the protein can be uniquely identified before the sequence length reaches an upper limit, the sequence length is displayed (S9). If the sequence length has reached the upper limit without successful identification, a message saying that the protein cannot be identified is displayed (S11).
Owner:SHIMADZU CORP

Method for making targeted therapeutic agents

ActiveUS9193795B2Rapid and efficient identification and isolation and productionEffective and low methodAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsDisease markersCross linker
Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair.
Owner:PROTEONOVA

Cell membrane penetrating conjugates

A cell penetrating conjugate comprising a recombinant β helical protein linked to a functional molecule wherein the β helical protein length is in the range of from 5 nm to 25 nm, suitably, from 10 nm to 15 nm and width is in the range of from 1 nm to 5 nm, suitably, from 1 nm to 3 nm. Processes for preparing said conjugates and uses thereof are also disclosed.
Owner:CYGENICA LTD

Process for production of a recombinant protein and a fusion protein

This invention provides a recombinant protein expression system using a host and cell-free translation system, and is capable of universally expressing a large amount of any protein as soluble protein, while preventing toxicity in hosts, formation of inclusion bodies, and decompositions with proteases. Such may be achieved by expressing the desired protein as a fusion protein with chaperoning, such as about 60 kDa molecular chaperons, 60 kDa heat shock proteins, or thermosomes, and accommodating the desired protein inside of a stereostructure of a chaperonin. The present invention provides a process for producing a protein, which comprises transcribing and translating a gene containing a gene encoding the linked chaperonin subunits and a gene encoding a desired protein thereby synthesizing a fusion protein having the desired protein linked via a peptide linkage to the linked chaperonin subunits.
Owner:SEKISUI CHEM CO LTD

Method of Producing Protein-Carbohydrate Vaccines Reduced in Free Carbohydrate

This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate.
Owner:FINA BIOSOLUTIONS

Cross-linked hyaluronic acid hydrogels comprising proteins

The invention relates to the field of derivatized cross-linked hyaluronic acid hydrogels having blood-derived proteins linked into their structure, as well as preparation and uses thereof.
Owner:LACERTA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products